RxDoctor Payments Data

Michael Hymbaugh

Internal Medicine · Baton Rouge, LANPI 1053529727

Payments from drug & device makers

$16,008in general payments, 2019–2025

Across 264 payments — averaging $60.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$12K
  • Viiv Healthcare Company$2K
  • Janssen Products, LP$547
  • Merck$376
  • Napo Pharmaceuticals Inc$285
  • Johnson & Johnson$164
  • plus $395 from 10 others

What the payments were for

  • Consulting fees$7,11044%
  • Speaking & faculty fees$991%
  • Travel & lodging$2,53016%
  • Food & beverage$5,95037%
  • Education$3192%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,008 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala98$345,075
JulucaDolutegravir/Rilpivirine97$303,198
DovatoDolutegravir Sodium/Lamivudine67$180,530
TivicayDolutegravir Sodium50$113,529
OdefseyEmtricitab/Rilpiviri/Tenof Ala32$111,159
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf17$85,069
CabenuvaCabotegravir/Rilpivirine17$80,698
DescovyEmtricitabine/Tenofov Alafenam31$60,303
TriumeqAbacavir/Dolutegravir/Lamivudi13$48,647
OzempicSemaglutide34$30,125
RybelsusSemaglutide26$25,049
PifeltroDoravirine16$24,883
TrulicityDulaglutide26$20,018
JardianceEmpagliflozin21$12,322
Incruse ElliptaUmeclidinium Bromide14$4,711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyJuluca, Dovato, Tivicay, Cabenuva, Triumeq$1,989$726,601244 claims
GileadBiktarvy, Descovy$12,253$405,378129 claims
Janssen Products, LPSymtuza$547$85,06917 claims
MerckPifeltro$376$24,88316 claims
Lilly USA, LLCTrulicity$45$20,01826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →